Alibaba will pay $600 million as the United States intensifies its efforts to combat illegal drug sales
Alibaba is set to pay a $600 million settlement following an investigation by US authorities into illegal drug sales occurring on its platforms.
Chinese technology and e-commerce giant Alibaba, along with its U.S.-based payment processor, will pay $600 million to settle allegations of failing to prevent illegal drug sales, as stated by the United States Department of Justice.
The Justice Department announced on Wednesday that Alibaba and AUS Merchant Services have agreed, as part of the deal, to take responsibility for the actions of their officers and employees and to improve their compliance programs.
The companies reached non-prosecution agreements to address allegations of violating the US Federal Food, Drug, and Cosmetic Act by allowing merchants to sell and import illegal drugs, chemicals, and pill presses into the US via Alibaba’s e-commerce platforms.
“This settlement demonstrates a comprehensive regulatory process with Alibaba’s complete cooperation and our dedication to top-tier standards of control, policies, and measures against non-compliant product sales,” Alibaba stated.
According to the Justice Department, Alibaba acknowledged that it did not succeed in preventing approximately 80,000 sales of chemicals, drugs, and counterfeit pharmaceutical equipment imported from abroad between 2016 and 2024 as part of the agreement.
According to the Justice Department, those transactions had a total merchandise value exceeding $200 million.
Law enforcement conducted over 40 undercover purchases of illegal pharmaceuticals and counterfeiting equipment during the investigation, it stated.
At times, employees at Alibaba expressed concerns regarding the sale of illegal products and questioned the adequacy of the company’s compliance measures in preventing such sales, according to the department.
Law enforcement officers from various US government agencies carried out over 40 undercover purchases of pharmaceuticals and equipment that were prohibited from being imported into the US, as stated in a news release regarding the settlement resolution.
The US government stated that the anti-money laundering compliance program of the US-based payment processor was ineffective in preventing certain merchants from utilizing its services to facilitate the sale and importation of prohibited products.
“Today’s resolution demonstrates the Department of Justice’s dedication to ensuring that companies involved in e-commerce and digital payment platforms prevent illegal, unapproved, misbranded, and hazardous foreign pharmaceuticals from entering their marketplaces,” Brett Shumate stated.
Alibaba runs some of the biggest e-commerce platforms globally, such as Alibaba.com and AliExpress.com.
